DK1267945T3 - Genetisk modificerede celler der udtrykker en TGF-beta-inhibitor, hvor cellerne er lungecancerceller - Google Patents

Genetisk modificerede celler der udtrykker en TGF-beta-inhibitor, hvor cellerne er lungecancerceller

Info

Publication number: DK1267945T3
Authority: DK; Denmark
Prior art keywords: cells; lung cancer; genetically modified; tgf; beta inhibitor
Prior art date: 2000-03-31

Application number

DK01926498.5T

Other languages

English (en)

Inventor

Habib Fakhrai

Original Assignee

Novarx

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-31

Filing date

2001-03-30

Publication date

2011-10-31

2001-03-30 Application filed by Novarx filed Critical Novarx

2011-10-31 Application granted granted Critical

2011-10-31 Publication of DK1267945T3 publication Critical patent/DK1267945T3/da

Links

239000003112 inhibitor Substances 0.000 title abstract 2
206010058467 Lung neoplasm malignant Diseases 0.000 title 1
102000004887 Transforming Growth Factor beta Human genes 0.000 title 1
108090001012 Transforming Growth Factor beta Proteins 0.000 title 1
201000005202 lung cancer Diseases 0.000 title 1
208000020816 lung neoplasm Diseases 0.000 title 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
206010041067 Small cell lung cancer Diseases 0.000 abstract 2
208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
208000000587 small cell lung carcinoma Diseases 0.000 abstract 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
230000002068 genetic effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001134—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Oncology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK01926498.5T 2000-03-31 2001-03-30 Genetisk modificerede celler der udtrykker en TGF-beta-inhibitor, hvor cellerne er lungecancerceller DK1267945T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19349700P	2000-03-31	2000-03-31
PCT/US2001/010339 WO2001074404A2 (en)	2000-03-31	2001-03-30	Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor

Publications (1)

Publication Number	Publication Date
DK1267945T3 true DK1267945T3 (da)	2011-10-31

Family

ID=22713877

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01926498.5T DK1267945T3 (da)	2000-03-31	2001-03-30	Genetisk modificerede celler der udtrykker en TGF-beta-inhibitor, hvor cellerne er lungecancerceller

Country Status (8)

Country	Link
EP (2)	EP1267945B8 (da)
JP (2)	JP5079962B2 (da)
AT (1)	ATE526990T1 (da)
AU (1)	AU2001253031A1 (da)
DK (1)	DK1267945T3 (da)
ES (1)	ES2373431T3 (da)
PT (1)	PT1267945E (da)
WO (1)	WO2001074404A2 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7101543B2 (en)	2000-03-31	2006-09-05	Novarx	Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
US8293252B2 (en) *	2006-12-20	2012-10-23	Novarx Corporation	Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization
JP6410237B2 (ja) *	2012-11-09	2018-10-24	マルコアーケッティ	拡散性因子および癌細胞

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5116742A (en)	1986-12-03	1992-05-26	University Patents, Inc.	RNA ribozyme restriction endoribonucleases and methods
US4987071A (en)	1986-12-03	1991-01-22	University Patents, Inc.	RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en)	1987-06-11	1990-02-27	Synthetic Genetics	Novel amphiphilic nucleic acid conjugates
ES2144426T3 (es) *	1991-10-25	2000-06-16	Sidney Kimmel Cancer Ct	Terapia genica linfoquimica del cancer en combinacion con antigenos tumorales.
US5772995A (en) *	1994-07-18	1998-06-30	Sidney Kimmel Cancer Center	Compositions and methods for enhanced tumor cell immunity in vivo
US5824655A (en) *	1995-02-15	1998-10-20	The University Of Utah	Anti-transforming growth factor-β gene therapy

2001
- 2001-03-30 AT AT01926498T patent/ATE526990T1/de active
- 2001-03-30 ES ES01926498T patent/ES2373431T3/es not_active Expired - Lifetime
- 2001-03-30 DK DK01926498.5T patent/DK1267945T3/da active
- 2001-03-30 EP EP01926498A patent/EP1267945B8/en not_active Expired - Lifetime
- 2001-03-30 PT PT01926498T patent/PT1267945E/pt unknown
- 2001-03-30 AU AU2001253031A patent/AU2001253031A1/en not_active Abandoned
- 2001-03-30 WO PCT/US2001/010339 patent/WO2001074404A2/en not_active Ceased
- 2001-03-30 EP EP10178154A patent/EP2314322A1/en not_active Withdrawn
- 2001-03-30 JP JP2001572145A patent/JP5079962B2/ja not_active Expired - Fee Related
2012
- 2012-06-21 JP JP2012139658A patent/JP2012176994A/ja active Pending

Also Published As

Publication number	Publication date
JP2003528930A (ja)	2003-09-30
JP5079962B2 (ja)	2012-11-21
WO2001074404A2 (en)	2001-10-11
WO2001074404A3 (en)	2002-10-17
EP1267945A2 (en)	2003-01-02
EP1267945B1 (en)	2011-10-05
PT1267945E (pt)	2011-12-28
EP2314322A1 (en)	2011-04-27
JP2012176994A (ja)	2012-09-13
AU2001253031A1 (en)	2001-10-15
ATE526990T1 (de)	2011-10-15
EP1267945B8 (en)	2012-03-21
ES2373431T3 (es)	2012-02-03

Similar Documents

Publication	Publication Date	Title
TR200000481T2 (tr)	2000-06-21	N-Alkonoilfenilalenin türevleri.
EP1497435A4 (en)	2005-07-27	STEM CELLS DERIVED FROM PLAZENTA AND THEIR USES
AU2002214596A1 (en)	2002-04-22	Methods and compositions for nucleic acid delivery
RU2000106434A (ru)	2004-01-20	N-алканоилфенилаланиновые производные
DE60144517D1 (de)	2011-06-09	Rekombinante konstrukte und ihre verwendung bei der reduzierung der genexpression
WO2000009706A3 (en)	2000-11-16	Maize cellulose synthases and uses thereof
CY1116768T1 (el)	2017-03-15	Συνθεσεις οι οποιες περιεχουν βλαστοκυτταρα θηλυκης γαμετικης σειρας και μεθοδοι χρησης αυτων
BR0116452A (pt)	2003-09-30	Composto, composição farmacêutica, uso de um composto
BR0108396A (pt)	2003-03-11	Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
TR200200068T2 (tr)	2002-05-21	Nematisital triflüorobütenler
EP1546174A4 (en)	2007-05-09	METHOD AND COMPOSITIONS FOR RNA INTERFERENCE
WO2004013093A3 (en)	2004-07-01	Cytotoxic agents containing novel potent taxanes and their therapeutic use
NO20070373L (no)	2007-01-31	Aerosol suspensjonsformulering inneholdende TG 227 EA eller TG 134 A som et drivmiddel
YU40402A (sh)	2005-03-15	4-pirimidinil-n-acil-l-fenilalanini
BR0215392A (pt)	2004-12-07	Composições farmacêuticas compreendendo um inibidor de fosfodiesterase multifuncional e um inibidor de absorção de adenosina, bem como uso das mesmas
DK1526840T3 (da)	2008-11-03	Nanopartikler til DNA administration til et målorgan
EP1368467A4 (en)	2005-09-07	Putrescine N-METHYLTRANSFERASEPROMOTOR
AU7548500A (en)	2001-04-24	Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
ATE499098T1 (de)	2011-03-15	Verwendung von parp-1-hemmern
TR199802649A2 (xx)	1999-07-21	Sikline ba�l� kinazlar�n inhibit�rleri i�in ba�lama e�leri.
SE0003476D0 (sv)	2000-09-28	Compounds
DK1267945T3 (da)	2011-10-31	Genetisk modificerede celler der udtrykker en TGF-beta-inhibitor, hvor cellerne er lungecancerceller
DE60016429D1 (de)	2005-01-05	Zell- und/oder tumor-spezifische promotor-abhängige änderung der gezielten expression des herpes gamma 34.5 gens
ATE335824T1 (de)	2006-09-15	Isolierte luziferasen sowie deren verwendung
EP1558086A4 (en)	2008-03-05	Cell taring process and compositions